William John Sibold sold $1.4M of MDGL
President and CEO at MADRIGAL PHARMACEUTICALS, INC.. 2,400 shares at an average of $575.34, traded Dec 4, 2025, filed Dec 4, 2025.
Score components
- +25RoleCEO
- +25Trade size$1.4M at market
- 0Share of holdings soldSold 1.6% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-055430, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 3, 2025 | MOption exercise Common Stock | +50,000 | - | - | 152,474 | Dec 4, 2025 |
| Dec 4, 2025 | SOpen-market sale Common Stock | -2,400 | $575.34 | $1.4M | 150,074 | Dec 4, 2025 |
| Dec 3, 2025 | MOption exercise Performance Restricted Stock Unitsderivative | -50,000 | - | - | 0 | Dec 4, 2025 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 25Weak | MADRIGAL PHARMACEUTICALS, INC. | Paul A Friedman director | $14M 24,800 shares | -12% | |
| 20Weak | MADRIGAL PHARMACEUTICALS, INC. | Rebecca Taub director | $10M 18,650 shares | -4% | |
| 37Weak | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier EVP and CFO | $2.4M 4,173 shares | -29% | |
| 40Moderate | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $1.1M 1,958 shares | -16% | |
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | Richard S Levy director | $4.4M 8,500 shares | -29% | |
| 53Moderate | MADRIGAL PHARMACEUTICALS, INC. | Kenneth Bate director | $8.0M 16,575 shares | -86% | |
| 50Moderate | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $3.2M 7,279 shares | -7% | |
| 45Moderate | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $3.0M 7,616 shares | -6% | |
| 46Moderate | MDGLbuy MADRIGAL PHARMACEUTICALS, INC. | Baker Bros. Advisors LP director | $25M 68,618 shares | +36% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.